An evidence-based review of linezolid for the treatment of methicillin-resistant Staphylococcus aureus (MRSA): place in therapy
Richard Watkins
Core Evidence, 2012
View PDFchevron_right
In-vitro activity of Linezolid and other antimicrobial agents against methicillin resistant staphylococci
Abdulaziz Zorgani
View PDFchevron_right
PP-002 Comparison of in vitro efficacy of linezolid and vancomycin against methicillin resistant Staphylococcus aureus (MRSA)
Ali Irfan Khalid
International Journal of Infectious Diseases, 2010
View PDFchevron_right
Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA)
Kamal Itani
International Journal of Antimicrobial Agents, 2005
View PDFchevron_right
European perspective and update on the management of complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid
Matthew Dryden
Clinical Microbiology and Infection, 2014
View PDFchevron_right
PP-004 Comparison of in vitro efficacy of linezolid, tigecycline and chloramphenicol against methicillin resistant Staphylococcus aureus (MRSA) isolated from tertiary care hospital of Pakistan
Ali Irfan Khalid
International Journal of Infectious Diseases, 2010
View PDFchevron_right
Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus
Matthew Dryden
The American Journal of Surgery, 2010
View PDFchevron_right
Comparison of in vitro efficacy of linezolid and vancomycin by determining their minimum inhibitory concentrations against methicillin resistant Staphylococcus aureus (MRSA)
Fatima Kaleem
JPMA. The Journal of the Pakistan Medical Association, 2011
View PDFchevron_right
Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan
Kazuhiro Yamaguchi
Journal of Antimicrobial Chemotherapy, 2007
View PDFchevron_right
Linezolid eradicates MRSA better than vancomycin from surgical-site infections
Haytham Kaafarani
The American Journal of Surgery, 2004
View PDFchevron_right
Linezolid resistance in clinical isolates of Staphylococcus aureus
Ortrud Zimmermann
Journal of Antimicrobial Chemotherapy, 2003
View PDFchevron_right
Clinical and Microbiological Effect of Linezolid on Methicillin-Resistant Staphylococcus aureus (MRSA) Colonization in Healthcare Workers in Egypt
Noha Gamal
View PDFchevron_right
Linezolid versus Vancomycin in Treatment of Complicated Skin and Soft Tissue Infections
Kamal Itani
Antimicrobial Agents and Chemotherapy, 2005
View PDFchevron_right
Comparison of vancomycin and linezolid in patients with peripheral vascular disease and/or diabetes in an observational European study of complicated skin and soft-tissue infections due to methicillin-resistant Staphylococcus aureus
Seema Haider
Clinical Microbiology and Infection, 2015
View PDFchevron_right
Early experience with linezolid for infections in orthopaedics
Paul Harwood
Injury, 2006
View PDFchevron_right
Efficacy of linezolid against Staphylococcus aureus in different rodent skin and soft tissue infections models
Dilip Upadhyay
Microbiology Research, 2011
View PDFchevron_right
In-vitro susceptibility of linezolid against methicillin resistant Staphylococcus aureus at a tertiary care hospital in Pakistan
Ali Irfan Khalid
Journal of Microbiology and Infectious Diseases
View PDFchevron_right
Correlation between oxacillin MIC values with those of linezolid against clinical isolates of MRSA
Innovative Publication
Indian Journal of Microbiology Research, 2023
View PDFchevron_right
Pharmacokinetics and penetration of linezolid into inflamed soft tissue in diabetic foot infections
Gundolf Haase
European Journal of Clinical Pharmacology, 2008
View PDFchevron_right
In vitro activity of linezolid against clinical isolates of methicillin resistant Staphylococcus
Abdul Hannan
J Ayub Med Coll …, 2009
View PDFchevron_right
Therapeutic Dose Monitoring for Linezolid in a Patient with MRSA Pneumonia with Bacteremia in Diabetes Insipidus
Hiroyasu Ishikura
Infectious diseases and therapy, 2015
View PDFchevron_right
In vitro activity of linezolid in combination with doxycycline, fosfomycin, levofloxacin, rifampicin and vancomycin against methicillin-susceptible Staphylococcus aureus
Jose Arce
View PDFchevron_right
Linezolid Alone or Combined with Rifampin against Methicillin-Resistant Staphylococcus aureus in Experimental Foreign-Body Infection
Daniela Baldoni
Antimicrobial Agents and Chemotherapy, 2009
View PDFchevron_right
In vitro and in vivo activities of linezolid alone and combined with vancomycin and imipenem against Staphylococcus aureus with reduced susceptibility to glycopeptides
Francesc Gudiol
European Journal of Clinical Microbiology & Infectious Diseases, 2010
View PDFchevron_right
Clinical Experience With Linezolid in Conjunction With Wound Coverage Techniques for Skin and Soft-Tissue Infections and Postoperative Osteomyelitis
Jerome Schentag
Annals of Plastic Surgery, 2004
View PDFchevron_right
Influence of the MBC/MIC ratio on the antibacterial activity of vancomycin versus linezolid against methicillin-resistant Staphylococcus aureus isolates in a pharmacodynamic model simulating serum and soft tissue interstitial fluid concentrations reported in diabetic patients
Natalia González
Journal of Antimicrobial Chemotherapy, 2013
View PDFchevron_right
Vancomycin, Linezolid, and Ceftaroline In vitro Activity Against Methicillin susceptible Staphylococcus aureus (MSSA) and Methicillin-resistant Staphylococcus aureus (MRSA) Isolates
Eny Purwoningsih
Pharmacognosy Journal
View PDFchevron_right
Detection of in-vitro Activity of Linezolid in Methicillin Resistant Staphylococcus aureus Infections by E-test
Smitha Bagali
2015
View PDFchevron_right
Efficacy of Linezolid in Treatment of Experimental Endocarditis Caused by Methicillin-Resistant Staphylococcus aureus
john gibson
Antimicrobial Agents and Chemotherapy, 2001
View PDFchevron_right
In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods
Pierre-Yves Donnio
Journal of Antimicrobial Chemotherapy, 2003
View PDFchevron_right
In Vivo Efficacy of Continuous Infusion versus Intermittent Dosing of Linezolid Compared to Vancomycin in a Methicillin-Resistant Staphylococcus aureus Rabbit Endocarditis Model
Jocelyne Caillon, Cédric Jacqueline, Gilles Potel
Antimicrobial Agents and Chemotherapy, 2002
View PDFchevron_right
In Vitro Bactericidal Activities of Linezolid in Combination with Vancomycin, Gentamicin, Ciprofloxacin, Fusidic Acid, and Rifampin against Staphylococcus aureus
M. Kitzis, P. Grohs
Antimicrobial Agents and Chemotherapy, 2003
View PDFchevron_right
In vitro susceptibility of methicillin-resistant Staphylococcus aureus isolates from skin and soft tissue infections to vancomycin, daptomycin, linezolid, and tedizolid
Judy Natalia Jiménez-Quiceno
The Brazilian Journal of Infectious Diseases, 2017
View PDFchevron_right